Navigation Links
Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones
Date:3/4/2008

in the Company's Form 10-K for the fiscal year ended

December 31, 2006

Vermillion, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(In Thousands, Except Per Share Amounts)

(Unaudited)

Three Months Ended Year Ended

December 31, December 31,

2007 2006 2007 2006

Revenue $23 $1,216 $44 $18,215

Cost of revenue 13 506 28 9,338

Gross profit 10 710 16 8,877

Operating expenses:

Research and

development 1,916 2,693 8,213 11,474

Sales and marketing 735 1,916 2,175 12,568

General and

administrative 2,232 3,112 10,858 10,661

Total operating expenses 4,883 7,721 21,246 34,703

Gain on sale of

instrument business 1,992 6,929 1,610 6,929

Loss from operations (2,881) (82) (19,620) (18,897)

Loss on extinguishment

of debt - (1,481) - (1,481)

Interest and other

expense, net (247) (326) (1,499) (1,536)

Loss before income

taxes (3,128) (1,889) (21,119) (21,914)

Income tax benefit

(expense) (164) 38 (163) (152)

Net loss $(3,292) $(1,851) $(21,282) $(22,066)

Loss per share -

basic and diluted (1) $(0.52) $(0.49) $(4.47) $(6.05)

Shares used to

compute basic and

diluted loss per

common sha
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
2. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
3. Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
4. Vermillion to Webcast Presentation at the Acumen BioFin 9th Annual Healthcare Conference, November 5-7, New York
5. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
6. Vermillion Receives NASDAQ Notice of Non-Compliance
7. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
8. Vermillion Announces Effectiveness of Reverse Stock Split
9. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
10. Access Highlighted in Recent BusinessWeek Article
11. ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... OAKS, Calif. , July 25, 2014 ... Board of Directors today declared a $0.61 per share ... will be paid on Sept. 5, 2014, to all ... on Aug. 14, 2014.  About Amgen ... for patients suffering from serious illnesses by discovering, developing, ...
(Date:7/25/2014)... , July 25, 2014 ... the "Global Metabolomics Market 2014-2018" report ... http://photos.prnewswire.com/prnh/20130307/600769 Metabolomics or Metabonomics is ... Metabolomics has become a new experimental technique that ... the environmental sciences. Metabolites are small molecules that ...
(Date:7/25/2014)... July 25, 2014 The Conferee Networking ... Topics for Conferee Networking. These two-hour sessions provide a ... meet and resolve problems, discuss new techniques, or brainstorm ... to submit a topic for consideration is August 31, ... . The Conferee Networking committee will review the topics, ...
(Date:7/25/2014)... 2014 /PRNewswire-iReach/ -- Xybion Corporation, the leading provider ... operating in highly regulated industries, announced today that ... User Group Conference, Xybion International Exchange, on October ... at the Sheraton Society Hill Hotel.  ... This year,s conference theme is Compliance ...
Breaking Biology Technology:Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3
... Jan. 24 Cardica, Inc.,(Nasdaq: CRDC ) ... fiscal 2008 second quarter and six months ended ... excellent commercial progress, with over 1,000,C-Port systems shipped ... an expanding,product line designed to enable minimally-invasive cardiac ...
... FRAZER, Pa. and MAISONS-ALFORT, France, Jan. 24 /PRNewswire-FirstCall/,-- ... that the European,Committee for Medicinal Products for Human ... a positive opinion regarding EFFENTORA(TM), the,company,s fentanyl buccal ... EFFENTORA European new drug application for the treatment ...
... DIEGO, Jan. 24 Biomatrica, the biostability company,that ... temperature, has introduced RNAstable(TM) for preserving RNA at ... shipping., Interest in RNA has skyrocketed over ... gene silencer and in gene expression studies. However, ...
Cached Biology Technology:Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 2Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 3Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 4Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 5Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 6Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 7Cephalon's EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 2Cephalon's EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 3Cephalon's EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain 4Biomatrica's RNAstable(TM) Stabilizes RNA at Room Temperature 2Biomatrica's RNAstable(TM) Stabilizes RNA at Room Temperature 3
(Date:7/25/2014)... healthcare community and remain priority areas that ... the worldwide crisis of obesity and diabetes, ... in diabetes, epidemiology and public health describe ... of diverse intervention programs in this novel ... on "Global Health Perspectives in Prediabetes and ...
(Date:7/25/2014)... is a complex congenital central nervous system disease ... the neural tubes during the embryonic phase. Many ... fecal incontinence and neurocognitive retardation. Such problems decrease ... life. Researchers at Ankara Physical Medicine and Rehabilitation ... performance in children with SB, using the Pediatric ...
(Date:7/25/2014)... Institute for Medical Research have identified the functions ... crucial to triggering the mating process in mice. , ... mouse detect pheromones that indicate when a female is ... if the female mouse is ovulating and ready to ... mating. Stowers, researchers believe mice developed this system through ...
Breaking Biology News(10 mins):What constitutes an effective response to the global 'diabesity' tsunami? 2It takes two to court 2It takes two to court 3
... is uniquely a "dual" sense, in that the brain perceives ... nose rather than the mouth. In the August 18, 2005, ... of chocolate activated different brain regions according to whether the ... or through the nose. , In a joint research effort ...
... cancer melanoma, studying functional tissue rather than cell ... development, according to new research from a Howard ... School of Medicine. , Though multiple genetic alterations ... been able to establish a direct causal link ...
... a small molecule of RNA called microRNA ?a chemical cousin ... protein involved in the early development of heart muscle. , ... Nature, may aid scientists in their understanding of how a ... cell, as well as offer researchers a way to predict ...
Cached Biology News:Nose odors and mouth odors: The brain distinguishes 2Nose odors and mouth odors: The brain distinguishes 3Ibruprofen and other commonly used painkillers for treating inflammation may increase the risk of heart attack 2Ibruprofen and other commonly used painkillers for treating inflammation may increase the risk of heart attack 3MicroRNA tweaks protein that controls early heart development 2MicroRNA tweaks protein that controls early heart development 3
... is a unique alternative to traditional ... acetate-EDTA) electrophoresis buffers. Bionic Buffer allows ... running times, and high-resolution band separation. ... electrophoresis after dilution to working 1x ...
... fast and easy method for the ... from mammalian tissues. Most of the ... outer membranes. The kit contains extraction ... proteome profiling. Also included is a ...
The Mu-End™ Protein Truncation Kit provides a convenient method for generating a library of N-terminal and C-terminal protein deletions that can be expressed in E. coli....
Sufficient reagents for 50 applications.Mitochondria Isolation Kit Reagent A, 50 ml Mitochondria Isolation Kit Reagent B, 500 l Mitochondria Isolation Kit Reagent C, 70 ml...
Biology Products: